

DAFTAR PUSTAKA

- Åberg F., Danford, C.J., Thiele, M., Talbäck, M., Rasmussen, D.N., Jiang, Z.G., *et al.* 2021. A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. *Hepatol Comm*, 5(6): 1021–1035.
- Al-Khurri, L.E., Al-Khafaji, K.R., Al-Salihi, S.A., Alwaysi, S.A.A. & Al-Akayshi, R.J. 2009. Serum HCV-RNA levels in patients with chronic hepatitis C: Correlation with histological features. *Arab J Gastroenterol*, 10(1): 10–13. <http://dx.doi.org/10.1016/j.ajg.2009.03.003>.
- Alhawaris. 2019. Hepatitis C: Epidemiologi, Etiologi, dan Patogenitas. *Jurnal Sains dan Kesehatan*, 2(2): 139–150.
- Ali, A.A., Bajwa, M.A., Sehgal, S.K.S. 2015. Aspartate Aminotransferase-Alanine Aminotransferase Ratio Predicts Cirrhosis in Chronic Hepatitis C Patients. *JSZMC*, 6(1): 760–762.
- Ali, N. & Siddiqui, A. 1995. Interaction of polypyrimidine tract-binding protein with the 5' noncoding region of the hepatitis C virus RNA internal initiation of translation. *J.Virol.*, 69(10): 6367–6375.
- Argentini, C., Genovese, D., Dettori, S. & Rapicetta, M. 2009. HCV genetic variability: From quasispecies evolution to genotype classification. *Future Microbiol.*, 4(3): 359–373.
- Aryati. 2010. Diagnosis Molekul dan Aplikasi dalam Pengobatan Hepatitis B dan C. *Indonesian Journal of Clinical Pathology and Medical Laboratory*, 16(2): 88–92.
- Bacon, B.R. 2015. Harrison's: Principle of Internal Medicine. In: Kasper, D.L., Hauser, S.L., Longo, D.L., Isselbacher, K.J., Wilson, J.D., Martin, J.B., Fauci, A.S., editors, *Chirrosis and It's Complications*. 19thed., Mc Graw-Hill Education, New York.
- Bagaglio, S., Messina, E., Hasson, H., Galli, A., Uberti-Foppa, C. & Morsica, G. 2019. Geographic distribution of HCV-GT3 subtypes and naturally occurring resistance associated substitutions. *Viruses*, 11: 1–15.
- Bandiera, S., Billie Bian, C., Hoshida, Y., Baumert, T.F. & Zeisel, M.B. 2016. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. *Curr Opin Virol*, 20: 99–105.
- Bantel, H., Lügering, A., Poremba, C., Lügering, N., Held, J., Domschke, W., Schulze-Osthoff, K., *et al.* 2001. Caspase activation correlates with the degree of inflammatory liver injury in chronic Hepatitis C virus infection. *Hepatology*, 34(4): 758–767.
- Bartenschlager, R. & Lohmann, V. 2000. Replication of hepatitis C virus. *Journal of General Virology*, 81(7): 1631–1648.
- Bisen, P.S., Prasad, G.B.K.S., Debnath, M. 2010. *Molecular Diagnostics: Promises and Possibilities*. Springer, London.
- Botros, M. & Sikaris, K.A. 2013. The De Ritis Ratio : The test of time The De Ritis Ratio : The Test of Time. *Clin Biochem Rev*, 34(11): 117–130.
- Chak, E., Talal, A.H., Sherman, K.E., Schiff, E.R. & Saab, S. 2011. Hepatitis C virus infection in USA: An estimate of true prevalence. *Liver International*,

- 31(8): 1090–1101.
- Chen, S.L. & Morgan, T.R. 2006. The natural history of hepatitis C virus (HCV) infection. *Int. J. Med. Sci.*, 3(2): 47–52.
- Chevaliez, S. & Pawlotsky, J.M. 2006. Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. *Int. J. Med. Sci.*, 3(2): 35–40.
- Crawford JW. 2009. Liver & billiary tract. In *Robbins and Cotran Pathologic Basis of Disease, Professional Edition - 8th Edition*. Philadelphia: Saunders.
- Craxi, A. 2014. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol*, 60(2): 392–420.
- Crovatto, M., Pozzato, G., Zorat, F., Pussini, E., Nascimben, F., Baracetti, S., *et al*. 2000. Peripheral blood neutrophils from hepatitis C virus-infected patients are replication sites of the virus. *Haematologica*, 85(4): 855–864.
- Deb, N., Lahon, D. & Sharma, P. 2016. A study on probable correlation of AST/ALT (De Ritis) ratio with the advancement of underlying severity of alcoholic liver disease in the North East Indian population. *Asian Pac. J. Health Sci.*, 3(2): 5–10.
- Diepolder, H.M., Zachoval, R., Hoffmann, R.M., Jung, M.C., Gerlach, T. & Pape, G.R. 1996. The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. *J Mol Med*, 74: 583–588.
- CDC Division of Viral Hepatitis. 2013. Viral Hepatitis Surveillance. pp:1-65
- Dustin, L.B., Bartolini, B., Capobianchi, M.R. & Pistello, M. 2016. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. *Clin Microbiol Infect.*, 22(10): 826–832. Available from: <http://dx.doi.org/10.1016/j.cmi.2016.08.025>.
- Fabris, P., Fleming, V., Giordani, M. & Barnes, E. 2008. Acute Hepatitis C: Clinical Aspects, Diagnosis, and Outcome of Acute HCV Infection. *Curr Pharm D*, 14(17): 1661–1665.
- Ghany, M.G., Strader, D.B., Thomas, D.L. & Seeff, L.B. 2009. Diagnosis, management, and treatment of hepatitis C: An update. *Hepatology*, 49(4): 1335–1374.
- Giannini, E, Botta, F, Fasoli, A, Ceppa, P, Risso, D, Lantieri, PB, Celle, G & Testa, R. 1999. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. *Digestive Diseases and Sciences*, 44(6): 1249–1253.
- Gower, E, Estes, C, Blach, S, Razavi-Shearer, K & Razavi, H. 2014. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol*, 61(1 Suppl): S45–S57. Available from: <http://dx.doi.org/10.1016/j.jhep.2014.07.027>.
- Gupta, E., Bajpai, M. & Choudhary, A. 2014. Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays. *Asian J Transfus Sci*, 8(1): 19–25.
- Hasan, K.N., Nasrin, F., Taher, M.A., Islam, S., Rahman, O., Jabeen, I., Khaleque, M.A., Akhteruzzaman, S. 2012. Comparative analysis of Hepatitis C Virus (HCV) RNA, Anti-HCV and Liver Transaminase levels as Markers and Predictors of infectivity in HCV infection. *BJMS*, 18(2): 120–125.

- Hassoba, H.M., Younis, S.E., Fahmy, H.A., Labib, S., Abdelrazek, N.Y., Youssef, A., El-Hadidy, G.S. & Metwally, L. 2010. Impact of hepatitis C virus infection on neutrophil oxidative burst function in hemodialysis patients. *The Egyptian Journal of Immunology*, 17(1): 1–8.
- Hiroishi, K., Eguchi, J., Ishii, S., Hiraide, A., Sakaki, M., Doi, H., Omori, R. & Imawari, M. 2010. Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection. *J Biomed Biotechnol*, 2010:263810.
- Huang, X.J., Choi, Y.K., Im, H.S., Yarimaga, O., Yoon, E. & Kim, H.S. 2006. Aspartate aminotransferase (AST/GOT) and alanine aminotransferase (ALT/GPT) detection techniques. *Sensors*, 6(7): 756–782. Available from: <https://doi.org/10.3390/s6070756>
- Jefferies, M., Rauff, B., Rashid, H., Lam, T. & Rafiq, S. 2018. Update on global epidemiology of viral hepatitis and preventive strategies. *World J Clin Cases*, 6(13): 589–599.
- Kayman, T., Karakucu, Ç. & Godekmerdan, A. 2013. Anti-HCV Pozitif Hastaların HCV RNA, Serum Transaminaz ve AST/ALT Oranlarının Değerlendirilmesi. *Viral Hepatit Dergisi*, 19(3): 99–102.
- Kim, I.H., Kisseleva, T. & Brenner, D.A. 2015. Aging and liver disease. *Curr Opin Gastroenterol.*, 31(3): 184–191.
- Kim, W.R., Flamm, S.L., Bisceglie, A.M. Di & Bodenheimer, H.C. 2008. Serum Activity of Alanine Aminotransferase (ALT) as an Indicator of Health and Disease. *Hepatology*, 47(4): 1363–1370.
- Kuo, M. Te, Hu, T.H., Lu, S.N., Hung, C.H., Wang, J.H., Chen, C.H., Chiu, Y.C. & Lee, C.M. 2014. Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin therapy for chronic hepatitis C. *Disease Markers*: 1–6.
- Lavanchy, D. 2009. The global burden of hepatitis C. *Liver International*, 29(Suppl 1): 74–81.
- Law, M., editor. 2019. *Hepatitis C Virus Protocols*. Methods in Molecular Biology 1911., Springer Protocols, New York.
- Li, H., Huang, M.H., Jiang, J.D. & Peng, Z.G. 2018. Hepatitis C: From inflammatory pathogenesis to antiinflammatory/hepatoprotective therapy. *World J Gastroenterol*, 24(47): 5297–5311.
- Li, X., Wang, L. & Gao, P. 2019. Chronic hepatitis C virus infection: Relationships between inflammatory marker levels and compensates liver cirrhosis. *Medicine*, 98(39): 1–6.
- Lo, Y.M.D. & Chan, K.C.A. 2006. Introduction to the polymerase chain reaction. *Methods in Molecular Biology*, 336:1–9. Available from: <https://doi.org/10.1385/1-59745-074-x:1>
- Lok, A.S. & Gunaratnam, N.T. 1997. Diagnosis of hepatitis C. *Hepatology*, 26(3 Suppl 1):48S–56S.
- Luedde, T. & Schwabe, R.F. 2011. NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma. *Nat. Rev. Gastroenterol. Hepatol.*, 8(2): 108–118. Available from: <http://dx.doi.org/10.1038/nrgastro.2010.213>.
- Luhmann, N., Champagnat, J., Golovin, S., Maistat, L., Agustian, E., Inaridze, I.,

- Myint, W.M., Butsashvili, M. & Bouscaillou, J. 2015. Access to hepatitis C treatment for people who inject drugs in low and middle income settings: Evidence from 5 countries in Eastern Europe and Asia. *Int J Drug Policy*, 26(11):1081–1087. Available from: <http://dx.doi.org/10.1016/j.drugpo.2015.07.016>.
- Lumongga, F. & Nur Anggraeni, R. 2017. Correlation Between Aspartate Aminotransferase/ Alanine Transferase Ratio (AST/ALT Ratio) and Stage of Liver Fibrosis in Patients with Chronic Hepatitis. *Advanced in Health Sciences Research*, 1(PHICo 2016): 72–75.
- Marcellin, P., Asselah, T. & Boyer, N. 2002. Fibrosis and disease progression in hepatitis C. *Jhep*, 36(5 (Suppl 1): s47–s56.
- Maudar, K.K., Gandhi, P., Mishra, P.K., Varshney, S., Punde, R. & Bhargav, A. 2012. Novel Approach for Quantification of Hepatitis C Virus in Liver Cirrhosis Using Real-Time Reverse Transcriptase PCR. *J Gastrointest Surg*, 16: 142–147.
- McGuinness, P.H., Bishop, G.A., Painter, D.M., Chan, R. & McCaughan, G.W. 1996. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. *Hepatology*, 23(4): 676–687.
- Mohasin, M., Nila, T., Sultana Tushy, T., Keya, K. & Enamul Haque, M. 2019. Correlation of serum alanine aminotransferase and hepatitis C viral RNA levels in Bangladeshi hepatitis patients. *Bioresearch Communications*, 5(1): 678–683.
- De Moliner, L., Pontisso, P., De Salvo, G.L., Cavalletto, L., Chemello, L. & Alberti, A. 1998. Serum and liver HCV RNA levels in patients with chronic hepatitis C: Correlation with clinical and histological features. *Gut*, 42(6): 856–860.
- Muljono, D.H. 2017. Epidemiology of hepatitis B and C in Republic of Indonesia. *Euroasian J Hepato-Gastroenterol*, 7(1): 55–59.
- Murray, P.R., Rosenthal, K.S., Pfaller, M.A. 2021. *Medical Microbiology*. 9th ed., Elsevier Inc. USA.
- Mutimer, D., Aghemo, A., Diepolder, H., Negro, F., Robaeys, G., Ryder, S., Zoulim, F., Peck, M., Craxi, A., Fried, M. & Zeuzem, S. 2014. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. *Journal of Hepatology*, 60(2): 392–420.
- Nar, R. & Milletti S.F. 2016. The Relationship Between the Serum RNA Titers of Hepatitis C Virus and Biochemical Parameters in Chronic Hepatitis C Patients. *Viral Hepatit Dergisi*, 22(1): 28–33.
- Oumaima, S., editor. 2014. Hepatitis C Virus: Molecular Pathways and Treatments. OMICS Group eBooks, USA.
- Paboriboune, P., Vial, T., Sitbounlang, P., Bertani, S., Trépo, C., Dény, P., Babin, F.X., Steenkeste, N., Pineau, P. & Deharo, E. 2018. Hepatitis C in Laos: A 7-Year Retrospective Study on 1765 Patients. *Virologica Sinica*, 33: 295–303.
- Park, G.J., Lin, B.P., Ngu, M.C., Jones, D.B. & Katelaris, P.H. 2000. Aspartate aminotransferase: Alanine aminotransferase ratio in chronic hepatitis C infection: Is it a useful predictor of cirrhosis?. *J Gastroenterol Hepatol*, 15(4): 386–390.
- Parmar, K.S., Singh, G.K., Gupta, G.P., Pathak, T., Nayak, S. 2016. Evaluation of

- De Ritis ratio in liver-associated diseases. *Int J Med Sci Public Health*, 5(9): 1783.
- Pawlotsky, J.M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M. & Wedemeyer, H. 2020. EASL recommendations on treatment of hepatitis C: Final update of the series. *Journal of Hepatology*, 73(5): 1170–1218.
- PPHI. 2014. *Konsensus Nasional Penatalaksanaan Hepatitis di Indonesia*. pp:1-16
- Prati, D., Shiffman, M.L., Diago, M., Gane, E., Rajender Reddy, K., Pockros, P., *et al.* 2006. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. *J Hepatol*, 44(4): 679–685.
- Rebbani, K. & Tsukiyama-kohara, K. 2016. HCV-Induced Oxidative Stress : Battlefield-Winning Strategy. *Oxid Med Cell Longev.*, 2016: 1-7.
- Reedy, D.W., Loo, A.T. & Levine, R.A. 1998. AST/ALT ratio ≥ 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. *Digestive Diseases and Sciences*, 43(9): 2156–2159.
- Reid, M., Price, J.C. & Tien, P.C. 2017. Hepatitis C Virus Infection in the Older Patient. *Infect Dis Clin N Am*, 31(4): 827–838.
- RISKESDAS. 2007. Result of National Basic Health Research. pp: 223-283.
- Roudot-Thoraval, F. 2021. Epidemiology of hepatitis C virus infection. *Clinics and Research in Hepatology and Gastroenterology*, 45(3): 1–6.
- Saif-Al-Islam, M., Mohamed, H.S., Younis, M.A., Abdelhamid, M.Y., Ali, M.M. & Khalaf, S. 2020. Impact of Gender Difference on Characteristics and Outcome of Chronic Hepatitis C. *ojpgas*, 10(11): 281–294.
- Santhi, D.D. 2015. Rasio De Ritis Pasien Hepatitis B di RSUP Sanglah, Denpasar. 1–10.
- Schiavon, J.L., Schiavon, L.L., Martins, T. 2010. Epidemiology of hepatitis C virus. *Rev Association Med Bras*, 57(1): 105–110.
- Sheehan, V.A., Weir, A. & Waters, B. 2014. Hepatitis C and neutropenia. *Curr Opin Hematol*, 21(1): 58–63.
- Sheth, S.G., Flamm, S.L., Gordon, F.D. & Chopra, S. 1998. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. *Am. Coll. of Gastroenterology*, 93(1): 44–48.
- Stasi, C., Silvestri, C. & Voller, F. 2020. Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to Elimination. *SN Compr. Clin. Med.*, 2020(18): 1-8.
- Sy, T. & Jamal, M.M. 2006. Epidemiology of hepatitis C virus (HCV) infection. *Int. J. Med. Sci.*, 3: 41–46.
- Syifa, M., Anita, K.W., Saputri, N.E.W. 2020. Hubungan Antara Rasio Neutrofil-Limfosit (RNL) dan Rasio Platelet-Limfosit (RPL) Dengan Kadar RNA VHC Pada Pasien Hepatitis C Kronik. *Majalah Kesehatan*, 7(3): 159–166.
- Ülger, Y. 2021. Is neutrophil lymphocyte ratio a useful biomarker in predicting fibrosis in chronic hepatitis c infection? *East J Med*, 26(1): 123–127.
- Ustündag Y, Bilezikçi B, Boyacioğlu S, Kayataş M, O.N. 2000. The utility of AST/ALT ratio as a non-invasive demonstration of the degree of liver fibrosis in chronic HCV patients on long-term haemodialysis. *Nephrol Dial Transplant*, 15(1716): 7.

- Vendemiale, G., Grattagliano, I., Portincasa, P., Serviddio, G., Palasciamo, G. & Altomare, E. 2001. Oxidative stress in symptom-free HCV carriers: Relation with ALT flare-up. *Eur J Clin Invest*, 31(1): 54–63.
- Vroon, D. & Israili, Z. 1990. Alkaline Phosphatase and Gamma Glutamyltransferase Clinical Methods: The History, Physical, and Laboratory Examinations. pp:492–493.
- Wait, S., Kell, E., Hamid, S., Muljono, D.H., Sollano, J., Mohamed, R., Shah, S., Mamun-Al-Mahtab, Abbas, Z., Johnston, J., Tanwandee, T. & Wallace, J. 2016. Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments. *Lancet Gastroenterol Hepatol*, 1: 248–255. Available from: [http://dx.doi.org/10.1016/S2468-1253\(16\)30031-0](http://dx.doi.org/10.1016/S2468-1253(16)30031-0).
- Wasley, A. & Alter, M.J. 2000. Epidemiology of hepatitis C: Geographic differences and temporal trends. *Semin Liver Dis.*, 20(1): 1–16.
- WHO. 2016. Guidelines for the screening, care and treatment of persons with hepatitis C infection. pp: 18-55.
- Woreta, T.A. & Alqahtani, S.A. 2014. Evaluation of abnormal liver tests. *Med Clin N Am*, 98(1): 1–16.
- Xu, R., Huang, H., Zhang, Z. & Wang, F.S. 2014. The role of neutrophils in the development of liver diseases. *Cell Mol Immunol.*, 11(3): 224–231. Available from: <http://dx.doi.org/10.1038/cmi.2014.2>.
- Yang, J.H., Lai, J.P., Douglas, S.D., Metzger, D., Zhu, X.H. & Ho, W.Z. 2002. Real-time RT-PCR for quantitation of hepatitis C virus RNA. *J Virol Methods*, 102(1–2): 119–128.
- Zein, N.N. 2000. Clinical significance of hepatitis C virus genotypes. *Clin. Microbiol. Rev.*, 13(2): 223–235.
- Zhao, L., Daw, M.A. & Shah, K.B. 2014. Hepatitis C Virus: Molecular Pathways and Treatments. *First*, (March): 3–13; 18–26; 27–29.